BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...Inc. (NASDAQ:ASTM) 9/11/14 $40.2 $60.7 $67.8 12% Immunovaccine Inc. (TSX-V:IMV) 8/26/14 $8.7 $83.8 $72.2 -14% Bioniche Life Sciences Inc....
BioCentury | Sep 1, 2014
Financial News

Bioniche completes follow-on

Bioniche Life Sciences Inc. (TSX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Date completed: 2014-08-22 Type: Follow-on Raised: C$5 million ($4.6 million) Shares: 21.8 million Price: C$0.23 (unit) Shares after offering: 164 million Underwriters: Dundee; Clarus Securities;...
BioCentury | Jun 9, 2014
Product Development

Bladder breakthrough

...compromises kidney function. The two most advanced treatments in the clinic for bladder cancer are Bioniche Life Sciences Inc....
...in the indication. Companies and Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. Bioniche Life Sciences Inc....
BioCentury | Jan 13, 2014
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Hired: Donald Olds as COO, formerly president and CEO of Presagia Corp. WIR Staff...
BioCentury | Jan 6, 2014
Company News

Agilis Biotherapeutics management update

...Neurology, Gene/Cell therapy Hired: George Zorich as CEO, formerly president of North American operations at Bioniche...
BioCentury | Jan 1, 2014
Company News

Agilis announces Intrexon deal, CEO and financing

...Securities. Other undisclosed new investors also participated. Zorich was president of North American operations at Bioniche...
BioCentury | Dec 16, 2013
Financial News

Bioniche financial update

...to delist on ASX next half and will continue trading on the Toronto Stock Exchange. Bioniche Life Sciences Inc....
BioCentury | Nov 11, 2013
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Hired: Michael Berendt as CEO, formerly president and CEO of Aegera Therapeutics Inc. , which Pharmascience Inc. acquired; he replaces Graeme McRae, who retired and...
BioCentury | Oct 14, 2013
Clinical News

Urocidin regulatory update

...NASDAQ:ENDP, Chadds Ford, Pa.) discontinued the Phase III EMBAR-RF trial of Urocidin and returned to Bioniche...
...valid patent claims covering the product has expired or been invalidated (see BioCentury, April 8). Bioniche Life Sciences Inc....
BioCentury | Oct 7, 2013
Financial News

Bioniche completes private placement of units

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Date completed: 9/26/13 Type: Private placement of units Raised: C$9.8 million ($9.5 million) Units: 33.8 million Price: C$0.29 (unit) Shares after offering: 139.4 million...
Items per page:
1 - 10 of 159
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...Inc. (NASDAQ:ASTM) 9/11/14 $40.2 $60.7 $67.8 12% Immunovaccine Inc. (TSX-V:IMV) 8/26/14 $8.7 $83.8 $72.2 -14% Bioniche Life Sciences Inc....
BioCentury | Sep 1, 2014
Financial News

Bioniche completes follow-on

Bioniche Life Sciences Inc. (TSX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Date completed: 2014-08-22 Type: Follow-on Raised: C$5 million ($4.6 million) Shares: 21.8 million Price: C$0.23 (unit) Shares after offering: 164 million Underwriters: Dundee; Clarus Securities;...
BioCentury | Jun 9, 2014
Product Development

Bladder breakthrough

...compromises kidney function. The two most advanced treatments in the clinic for bladder cancer are Bioniche Life Sciences Inc....
...in the indication. Companies and Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. Bioniche Life Sciences Inc....
BioCentury | Jan 13, 2014
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Hired: Donald Olds as COO, formerly president and CEO of Presagia Corp. WIR Staff...
BioCentury | Jan 6, 2014
Company News

Agilis Biotherapeutics management update

...Neurology, Gene/Cell therapy Hired: George Zorich as CEO, formerly president of North American operations at Bioniche...
BioCentury | Jan 1, 2014
Company News

Agilis announces Intrexon deal, CEO and financing

...Securities. Other undisclosed new investors also participated. Zorich was president of North American operations at Bioniche...
BioCentury | Dec 16, 2013
Financial News

Bioniche financial update

...to delist on ASX next half and will continue trading on the Toronto Stock Exchange. Bioniche Life Sciences Inc....
BioCentury | Nov 11, 2013
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Hired: Michael Berendt as CEO, formerly president and CEO of Aegera Therapeutics Inc. , which Pharmascience Inc. acquired; he replaces Graeme McRae, who retired and...
BioCentury | Oct 14, 2013
Clinical News

Urocidin regulatory update

...NASDAQ:ENDP, Chadds Ford, Pa.) discontinued the Phase III EMBAR-RF trial of Urocidin and returned to Bioniche...
...valid patent claims covering the product has expired or been invalidated (see BioCentury, April 8). Bioniche Life Sciences Inc....
BioCentury | Oct 7, 2013
Financial News

Bioniche completes private placement of units

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Date completed: 9/26/13 Type: Private placement of units Raised: C$9.8 million ($9.5 million) Units: 33.8 million Price: C$0.29 (unit) Shares after offering: 139.4 million...
Items per page:
1 - 10 of 159